OTR Global has a Positive read on Tandem Diabetes (TNDM) and Insulet (PODD) after interviews with U.S. endocrinology practitioners that showed new insulin pump start growth has remained “strong” and is expected to continue during 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes price target lowered to $50 from $57 at Citi
- Morgan Stanley upgrades ‘too cheap’ Tandem Diabetes to Overweight
- Tandem Diabetes upgraded to Overweight from Equal Weight at Morgan Stanley
- Tandem Diabetes price target raised to $60 from $58 at Barclays
- Tandem Diabetes price target lowered to $40 from $43 at UBS